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Abstract
Background: Clinical translation of mesenchymal stromal cells (MSCs) necessitates basic characterization of the cell
product since variability in biological source and processing of MSCs may impact therapeutic outcomes. Although
expression of classical cell surface markers (e.g., CD90, CD73, CD105, and CD44) is used to define MSCs, identification of
functionally relevant cell surface markers would provide more robust release criteria and options for quality control. In
addition, cell surface expression may distinguish between MSCs from different sources, including bone marrow-derived
MSCs and clinical-grade adipose-derived MSCs (AMSCs) grown in human platelet lysate (hPL).
Methods: In this work we utilized quantitative PCR, flow cytometry, and RNA-sequencing to characterize AMSCs grown
in hPL and validated non-classical markers in 15 clinical-grade donors.
Results: We characterized the surface marker transcriptome of AMSCs, validated the expression of classical markers,
and identified nine non-classical markers (i.e., CD36, CD163, CD271, CD200, CD273, CD274, CD146, CD248, and CD140B)
that may potentially discriminate AMSCs from other cell types. More importantly, these markers exhibit variability in cell
surface expression among different cell isolates from a diverse cohort of donors, including freshly prepared, previously
frozen, or proliferative state AMSCs and may be informative when manufacturing cells.
Conclusions: Our study establishes that clinical-grade AMSCs expanded in hPL represent a homogeneous cell culture
population according to classical markers,. Additionally, we validated new biomarkers for further AMSC characterization
that may provide novel information guiding the development of new release criteria.
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Background
Regenerative medicine endeavors to surpass traditional
treatments through the use of biological products to
restore damaged or diseased tissues that are otherwise
beyond repair. Integral to many regenerative therapeutic
strategies is the use of adult stem cells, and particularly
the use of mesenchymal stromal cells (MSCs) for either
their regenerative or immune-regulatory properties [1].
Currently, over 246 clinical trials utilizing allogenic or
autologous MSCs [2] are being performed worldwide to
treat various diseases including osteoarthritis [3], ath-
erosclerotic renal artery stenosis (ARAS) [4], multiple
system atrophy (MSA) [5], graft versus host disease [6],
and amyotrophic lateral sclerosis (ALS) [7]. Despite the
growing number of clinical trials, there are currently no
US FDA-approved MSC-based products [2]. Challenges
for clinical translation of MSC-based therapies largely
lie in the production and basic characterization of the
MSC product [2].
Cell therapy using MSCs is largely limited by the cell
harvesting and manufacturing of the MSC product. In
recent years, cell therapy research has moved away from
embryonic stem cells and induced pluripotent stem cells
due to ethical and safety concerns over these cell types.
Various alternative tissue sources of MSCs have been
identified, including bone marrow, adipose tissue, umbil-
ical cord, Wharton’s jelly, and gingival tissue. The major-
ity of studies utilize MSCs derived from the bone
marrow (BMSCs) owing to their potential to differenti-
ate into various mesenchymal tissues, including bone,
cartilage, and fat, as well as their immune-regulatory
functions. However, bone marrow as a source of MSCs
is limited by the invasive and painful aspiration proced-
ure, and very low abundance of MSCs that typically
account for 0.001–0.01 % of cells [8]. Adipose tissue has
been identified as an MSC-rich tissue, in which 1–10 %
of the stromal fraction is MSCs [9, 10], which also
undergo multi-lineage differentiation in vitro [9–13].
These attributes are advantageous and also permit
autologous transplantation, which is particularly important
for non-fatal diseases (e.g., wound healing, osteoarthritis,
or aesthetic procedures). Although the anatomical location
of harvesting may have some impact on the yield of
adipose-derived MSCs (AMSCs) [14, 15], variability in pro-
cessing, manufacturing, and delivery of MSC/AMSCs may
have larger implications on cell therapy outcomes [16].
AMSCs preparations for cell therapy vary from min-
imal processing (isolation of the stromal vascular frac-
tion) to ex vivo expansion of the processed lipoaspirate
[10]. The ex vivo expansion of AMSCs from the proc-
essed lipoaspirate is performed with either fetal bovine
or calf serum (FBS or FCS), or under nonzoonotic con-
ditions using human platelet lysate (hPL) [12, 17]. Previ-
ous studies have shown that culturing AMSCs in good
manufacturing practices (GMP)-grade hPL provides a
growth advantage, and the cellular yields were signifi-
cantly greater for AMSCs grown in 5 % hPL compared
to 10 % FBS or FCS [12, 17]. Tissue culture practices
may also influence AMSC growth, where contact inhib-
ition and/or cryopreservation may affect their function
[18–20]. Finally, the therapeutic delivery of MSCs also
varies among clinical trial protocols; MSCs are com-
monly cryopreserved, thawed, and administered, or
allowed to recover in culture for up to 4 days prior to
administration. It is currently not known how prepar-
ation procedures prior to administration may impact the
function of MSCs following infusion or application.
Despite differences in isolation, production, and ad-
ministration, characterization of an MSC-based product
is largely limited to measuring the expression of a subset
of classical cell surface markers, including CD90, CD73,
CD105, and CD44, and absence of expression of CD45
or CD31 as defined by the International Society for
Cellular Therapy (ISCT) and the International Feder-
ation of Adipose Therapeutics and Sciences (IFATS) [2,
11]. These markers only really serve to identify cells as
MSCs so additional markers are needed to get informa-
tion regarding potency and function of the cells, the
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differentiation potential, and how cultured cells change
over time during manufacturing. To gain a better under-
standing of the MSC surface proteome, techniques in-
cluding mass spectroscopy- and flow cytometry-based
antibody screening assays have been used to characterize
AMSC surface proteins and to determine the heterogen-
eity of MSC populations [21–26]. While these tech-
niques are highly relevant for screening purposes, these
studies have significant limitations in that they rarely
utilize clinical-grade AMSCs or report whether the cells
maintain homogeneity during manufacturing steps. As
such, product characterization remains an unmet need
for translational therapies using AMSCs. In this study,
we utilized clinical-grade AMSCs grown in GMP- hPL,
characterized the surface marker transcriptome of these
cells, and validated the expression of five classical and
nine non-classical markers.
Methods
Primary cell isolation and sample preparation for RNA
analysis
Primary bone cells
Bone tissue was mechanically disrupted using a scalpel
and resulting bone chips were plated onto tissue culture
dishes in complete media [advanced minimum essential
medium (MEM), 10 % phosphate-buffered saline (PBS),
100 U/ml penicillin, 100 g/ml streptomycin, 1x Gluta-
MAX] and maintained at 37 °C, 5 % CO2. Bone cells
were plated into new culture dishes and passaged three
times, at which time 1 × 106 cells were harvested for
RNA analysis.
Primary chondrocytes
Human cartilage was first digested with 0.2 % pronase in
complete media [Dulbecco’s modified Eagle’s medium
[DMEM]/F12 10 % FBS, 100 U/ml penicillin, 100 g/ml
streptomycin, 50 μg/mL gentamycin) for 1 h at 37 °C
with shaking in a cell culture incubator. Following incu-
bation with pronase, the cartilage was washed twice with
PBS, then incubated with 0.036 % collagenase-P over-
night at 37 °C in a cell culture incubator. The next day,
undigested cartilage was removed using a cell strainer
(BD Falcon) and flow-through containing primary
chondrocytes was pelleted and washed twice with
PBS. Primary chondrocytes were plated onto a tissue
culture plate and maintained at 37 °C, 5 % CO2, after
which 1 × 106 cells were harvested for RNA analysis.
Bone marrow-derived stromal cells
Primary human BMSC were purchased directly from
Lonza and expanded using our previously described pro-
cedures [27]. Cells were cultured up to passage 5 and
plated on standard tissue culture plastic until 70–80 %
confluent for harvest.
Fibroblasts
Primary human gingival fibroblasts (HGF) and human
periodontal ligament (HPDL) cells were established from
patient gingival connective tissue explants, as previously
described [28]. Cells were cultured at 37 °C in a 5 %
CO2/95 % air atmosphere in DMEM containing 10 %
FCS.
Real-time reverse transcriptase quantitative PCR analysis
Total RNA was isolated from primary cultured cells
using either Trizol® Reagent (Thermo) or miRNeasy
Mini Kit (Qiagen) according to respective protocols. The
SuperScript III First-Strand Synthesis System (Invitro-
gen) was used to reverse transcribe RNA into cDNA,
which was used as a template for real-time PCR analysis.
Real-time reactions were performed with 10 ng cDNA
per 10 μl with the QuantiTect SYBR Green PCR Kit
(Qiagen) and detected using the CFX384 Real-Time Sys-
tem (BioRad). Gene expression levels were normalized
to the housekeeping gene, GAPDH, and quantified using
the 2^(−delta delta Ct) method. Gene specific primers
are listed in Additional file 1: Table S1.
AMSC isolation and cell culture conditions
Mesenchymal stromal cells were derived from lipoaspi-
rates obtained from consenting donors and clinical trial
patients with approval from the Mayo Clinic Institutional
Review Board (IRB) as previously described [12, 29]. After
harvesting, fat tissue was digested with collagenase (type I
at 0.075 %; Worthington Biochemicals) for 1.5 h at 37 °C.
The stromal vascular fraction was isolated by low speed
centrifugation (400 g for 5 min), the supernatant was re-
moved, and the cell pellet was rinsed with PBS and passed
through a cell strainer (70 μm) (BD Biosciences). Buffered
ammonium solution (154 mM NH4Cl, 10 mM KHCO3,
0.1 mM EDTA) was used to lyse erythrocytes. The result-
ing cell fraction was plated onto tissue culture flasks in
standard culture medium (advanced MEM) with 5 % hPL
(Mill Creek Life Sciences), 2 mM L-glutamine (Invitro-
gen), and antibiotics (100 U/ml penicillin, 100 g/ml
streptomycin) and maintained 37 °C in 5 % CO2 at a cell
density of 1.0–2.5 × 103 cells/cm2.
Prior to cryopreservation, freshly isolated AMSCs were
harvested for flow cytometric analysis (pre-thaw sam-
ples), and the remaining cells were frozen in 1 ml ali-
quots of up to 20 × 106 cells/mL with CryoStor CS10
Cryopreservation Medium (BioLife Solutions, Stem Cell
Technologies) and stored in liquid nitrogen. Post-thaw
samples were recovered from cryopreservation by pla-
cing the vial in a 37 °C water bath to thaw, then trans-
ferred to 10 ml of growth media and centrifuged for
5 min at 500 g. Cells were resuspended in growth media
and approximately 1 × 106 cells were harvested for flow
cytometric analysis. The remaining thawed cells were
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plated in T-175 cm2 flasks at a density of up to 3000
cells/cm2 and cultured for 4 days at 37 °C in 5 % CO2.
After 4 days’ culture, cells were harvested for flow cyto-
metric analysis.
Flow cytometry
Cells were harvested from culture, and approximately
1 × 106 cells were added to tubes and centrifuged at 500
g for 5 min. The supernatant was removed and samples
were incubated with 50 μl of mouse serum for 5 min at
room temperature. Table 1 describes the antibodies and
antibody mixes. Primary antibody mixes were added to
respective tubes, vortexed, and incubated for 15 min at
room temperature in the dark. A total of 3 ml of PBSFE
[PBS with 5 mM NaEDTA (Sigma) and 1 % bovine
serum albumin (Sigma)] was added to each tube and
centrifuged at 500 g for 5 min. The supernatant was dis-
carded and 200 μl of 1 % paraformaldehyde (Electron
Microscopy Sciences) was added prior to acquisition.
The flow cytometric acquisition was performed on a
Beckman Coulter Gallios (Beckman Coulter). The cells
were acquired using forward scatter and side scatter and
gated to exclude debris. The cytometer acquired 50,000
AMSC events. The analysis was performed using Kaluza
software (Beckman Coulter), where population gates
were defined (%Gated) and mean fluorescence intensity
(MFI) values were generated by the software based on
fluorescence intensity of gated cell populations.
RNA-sequencing and bioinformatic analysis
Following RNA isolation using the miRNeasy Mini Kit
(Qiagen), RNA-seq was performed as previously de-
scribed [13]. Briefly, RNA was prepared for sequencing
using the TruSeq RNA Sample Prep Kit v2 (Illumina)
and was analyzed using Illumina HiSeq 2000 with Tru-
Seq SBS Kit v3 and HCS v2.0.12 data collection software.
Sequence data were processed using MAPRSeq (v.1.2.1)
and a bioinformatics workflow (TopHat 2.0.6, HTSeq,
and edgeR 2.6.2), where expression data were normal-
ized using the reads per kilobase per million (RPKM)
method.
RNA-seq data were further analyzed using the DAVID
Bioinformatics Resources 6.7 (https://david.ncifcrf.gov/)
[30, 31]. Hierarchical clustering was performed using
GENE-E (v3.0.228; Broad Institute, Cambridge, MA,
USA). RNA-seq data were deposited in the public Gene
Expression Omnibus (GEO) repository under the acces-
sion number [GEO:GSE84322].
Statistical analysis
Data were analyzed using GraphPad Prism v6 (GraphPad
Software) and are presented as mean and individual data
points. One-way ANOVA was used for multiple compar-
isons and post hoc analysis using Dunn’s multiple com-
parisons test was used to compare pre-freeze, post-thaw,
and 4-day culture, where significance was set at p < 0.05.
Results
AMSCs alter surface marker gene expression during
proliferating or confluent culture conditions
Production of clinical-grade AMSCs for cell therapy
must yield a consistent product and cell surface markers
are frequently used as part of the release criteria for
many laboratories. The release criteria used to
characterize AMSCs utilized herein are shown in Fig. 1a,
where AMSCs must express classical markers including
CD44, CD73, CD90, CD105, and HLA-ABC, and lack
the expression of HLA-DR, CD14, and CD45 [11]. We
found that the expression of these markers was homoge-
neous and uniform, with close to 100 % of gated cells
analyzed by flow cytometry either expressing positive
markers or lacking negative markers (Fig. 1b). All posi-
tive markers were consistently above 90 %, and negative
markers were expressed in <5 % of gated cells across the
different donors (Fig. 1c). The data presented here
support the literature demonstrating that these markers
are characteristic of AMSCs and are also present on
clinical-grade AMSCs expanded in hPL.
Table 1 List of antibodies used for flow cytometry validation
Antibody Fluorophore Company Catalog number
CD163 FITC Beckman Coulter B17492
CD140B PE BD 558821
CD248 Alexa Fluor 647a Abgent AP6756b
CD146 PC5 Beckman Coulter A22364
CD200 PE-Cy7 BD 562125
CD36 APC Beckman Coulter A87786
CD34 APC-A750 Beckman Coulter A89309
CD44 Pac Blu Beckman Coulter B37789
CD44 PC7 eBioscience 25-0441
CD276 APC eBioscience 17-2769-41
CD271 FITC Biolegend 345104
CD105 PE Beckman Coulter A07414
CD73 PerCP eFluor710 eBioscience # 46-0739-42
CD73 PE BD #550257
CD90 FITC Beckman Coulter IM1839U
CD274 PC7 Beckman Coulter A78884
CD14 ECD Beckman Coulter IM2707U
HLA-ABC APC eBioscience 17-9983
HLA-DR Pac Blu Beckman Coulter A74781
CD45 Krome Orange Beckman Coulter A96416
APC allophycocyanin, FITC fluorescein isothiocyanate, PC7 R-phycoerythrin
cyanin 7, PE R-phycoerythrin
a Custom Beckman Coulter-labeled antibody
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Identification of non-classical cell surface markers of
AMSCs and mesenchymal cells by high-throughput
quantitative PCR screening
The current AMSC cell surface markers were developed
to define cell populations with tri-lineage potential and
demonstrate only positive or negative characteristics.
However, the expression or absence of these markers is
unable to provide insight into the biological functions of
AMSCs. To identify non-classical surface markers that
are unique and have potential biological importance, we
developed a relative quantitative real-time PCR (qPCR)
panel of 69 cell surface genes based on proteomics stud-
ies of MSCs [21] and other markers from the literature.
Expression of classical markers using qPCR demon-
strated a higher abundance of transcripts for positive
markers compared to negative markers across four do-
nors of AMSCs (Fig. 2a), indicating that qPCR may be a
surrogate for flow cytometry for classical cell surface
markers.
Evaluation of the qPCR panel across four clinical-
grade AMSCs donors revealed 66/69 cell surface
markers were detected. Of the cell surface markers ana-
lyzed, CD248 was the most highly expressed gene and
demonstrated low co-variance between donor samples
(data not shown). The surface marker qPCR panel was
also used to analyze surface marker expression across
other mesenchymal cell types, including BMSCs, fibro-
blasts, bone outgrowth cells, and primary digest chon-
drocytes. Hierarchical clustering analysis was used to
compare AMSC surface markers to other cell types and
revealed distinct clusters for the different cell types. This
unsupervised analysis reveals that AMSCs form a unique
cluster and that these cells are most similar to fibro-
blasts and BMSCs (Fig. 2b). The clustering analysis dem-
onstrates that AMSCs are a distinct cell population and
may be identified using gene expression profiling tech-
niques for a panel of cell surface markers.
To develop a novel antibody panel that can distinguish
AMSCs from other mesenchymal cell types, including fi-
broblasts, we compared surface marker gene expression
between each lineage. Amongst the genes analyzed,
CD36 was highly specific to AMSCs, whereas CD140B,
CD271, and CD273 were able to discriminate AMSCs
from BMSCs and fibroblasts (Fig. 2c). Compared to bone
cells and chondrocytes, AMSCs did not express CD163,
CD146, CD200, or CD274. In addition, CD248 was the
cell surface marker most abundantly expressed by
AMSCs. Taken together, these nine markers were able to
distinguish AMSCs from other cell types. This demon-
strates that qPCR is a useful technique for identifying
informative markers for developing release criteria.
Flow cytometric validation of classical and non-classical
surface markers in a cohort of clinical-grade AMSCs
grown in human platelet lysate
Flow cytometry is the gold standard clinical tool for ana-
lyzing expression of cell surface markers and evaluating
the cell population composition in a sample. We per-
formed flow cytometry and characterized the expression
of classical MSC markers (CD34, CD73, CD105, CD44,
Fig. 1 Traditional phenotyping of clinical-grade adipose-derived mesenchymal stromal cells (AMSCs) expanded in human platelet lysate. a
Clinical-grade AMSCs grown in human platelet lysate were expanded ex vivo and immunophenotyped using flow cytometry according to the
release criteria presented in this table. b Representative flow cytometry scatter plots show AMSCs are a homogeneous population of cells and
exhibit surface expression of standard cell surface markers, including CD105, CD44, CD73, and CD90, and are negative for HLA-DR. c Analysis of
the flow cytometry release criteria across clinical-grade AMSCs from 15 donors demonstrated minimal variability in the population frequency
(% Gated) of the surface markers. All AMSC donor cells were >85 % positive for CD90, CD105, CD73, CD44, and HLA-ABC, and were <85 % positive for
HLA-DR, CD45, and CD14
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and CD90) (Fig. 3a). The surface localization of the nine
non-classical markers identified through gene expression
analysis (CD163, CD271, CD200, CD36, CD273, CD274,
CD146, CD248, and CD140b) was also validated across
15 clinical-grade AMSCs grown in hPL before
cryopreservation (Fig. 3b). Compared to classical
markers, expression of each of the non-classical markers
had greater donor-to-donor heterogeneity and abun-
dance (as indicated by MFI) across all donors. Among
the newly identified markers, CD276 demonstrated a
Fig. 2 Gene expression profiling and validation of cell surface markers across multiple mesenchymal cell types. a Gene expression of traditional
markers by adipose-derived mesenchymal stromal cells (AMSCs) was analyzed using quantitative PCR (qPCR). AMSCs have relatively high expression
levels of CD44, CD90, CD105, and CD73, and low or no expression of CD14 and CD45. To identify AMSC specific surface markers, high-throughput
qPCR screening of 69 surface markers curated from the literature was performed on various mesenchymal cell types, including AMSCs (n = 4), bone
marrow-derived stromal cells (BMSCs) (n = 2), primary bone cells (b) (n = 4), primary chondrocytes (C) (n = 4), and primary fibroblasts (F) (n = 4).
b Hierarchical clustering analysis of qPCR data across multiple cell types shows that AMSCs have a unique phenotype at the gene expression level.
c Comparison of different cell types revealed that classical surface markers, including CD44, CD73, and CD90, are expressed by not only AMSCs but also
other cell types. Furthermore, nine non-classical markers were selected based on differential expression between the various mesenchymal cells. These
markers, together with classical markers, were used to develop a novel antibody panel to characterize AMSCs
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similar expression pattern to the classical positive
markers, with >95 % cells gated expressing this marker
at robust levels (Fig. 3b). Conversely, CD163 was minim-
ally expressed, in <4 % of gated cells across all the do-
nors, indicating that this protein is not generally
expressed on AMSCs grown in hPL. Of the new markers
analyzed, CD271 and CD200 were distinguishable from
negative controls; however, they were expressed at low
levels among a small proportion of the population
(Fig. 3b). These results suggest that the manufacturing
procedure consistently isolated similar cell populations
from various donors. Furthermore, these data demon-
strates that eight out of nine non-classical markers are
expressed on AMSCs and that CD163 is a novel negative
marker of this population of cells.
Various post-transcriptional regulation mechanisms
can modulate the translation of mRNA to protein, and
may be a source of discrepancy in marker expression.
Figure 4 provides examples of qPCR and flow cytometry
data for two different AMSC donors across the non-
Fig. 3 Validation of nine non-classical markers by flow cytometry among 15 clinical-grade adipose-derived mesenchymal stromal cells (AMSCs).
Expression of five classical (a) and nine non-classical markers (b) was validated by flow cytometry across 15 additional freshly isolated and
expanded AMSC donors. Surface marker expression was evaluated by the percentage of the gated cell population and mean fluorescence
intensity (MFI). c Representative histograms of surface marker expression compared to unstained AMSCs (negative control). Of the non-classical markers,
CD36 exhibited two cell populations which varied from patient-to-patient
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classical markers. Markers that demonstrated similar
trends between the gene expression and percentage of
gated cells included CD248, CD276, CD36, CD163,
CD200, CD146, and CD271. Conversely, CD140b and
CD274 were not observed to show similar trends. These
data suggest that, for some surface markers, mRNA
expression may be a surrogate for protein expression.
Cell surface marker expression during various
manufacturing conditions
AMSCs are commonly administered for cell therapy by
one of three methods: (i) fresh expansion; (ii) cryopre-
served, thawed, and immediately administered; or (iii)
cryopreserved and allowed to recover in culture for up
to 4 days. To evaluate whether cryopreservation modu-
lated cell surface marker expression, we performed flow
cytometric analysis on samples from five donors at the
aforementioned clinically relevant time points (Fig. 5).
Classical markers CD44, CD90, CD105, and CD73 were
expressed by >90 % of gated cells across all three time
points (Fig. 5a). Among these markers, CD105 and
CD44 demonstrated a statistically significant increase in
gated cells following either cryopreservation or 4 days in
culture. The MFI for CD44 and CD105 also showed a gen-
eral trend for increased expression (Fig. 5a). CD73 fluores-
cence intensity was also significantly increased compared
to other classical markers, indicating a potential effect of
cryopreservation or adaptation to the culture environment.
These data suggest that classical markers are constitutively
expressed irrespective of manufacturing conditions.
We also evaluated the expression of non-classical
markers across the three manufacturing time points
Fig. 4 Expression of novel markers by quantitative PCR (qPCR) and flow cytometry. Gene expression data were compared to flow cytometry data
for two donors [adipose-derived mesenchymal cell (AMSC) donors 1 and 4]. Highly abundant markers showed good concordance (top panel)
between the techniques, whereas lower abundance markers showed variability (bottom panel). In particular, CD200 and CD274 were not
correlated. MFI mean fluorescence intensity
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(Fig. 5b). CD276 and CD140b were observed to exhibit a
similar expression pattern to classical markers, as >90 %
of gated cells were positive for these markers and were
unchanged over the different conditions. Furthermore,
the MFIs for these markers were significantly upregu-
lated by day four after recovery from cryopreservation
(Fig. 5b), which was also observed for the classical
marker CD73. However, the non-classical markers gen-
erally demonstrated greater donor-to-donor variability
compared to classical markers (Fig. 5b). In particular,
CD271 and CD36 were the only markers analyzed that
demonstrated a >20 % increase in the percentage of
positive cells by day four after thawing, whereas CD44
and CD105 only increased by 2.43 % and 0.34 %
Fig. 5 Effect of cryopreservation on surface marker expression. Flow cytometry for all 14 markers was performed on samples from 5 adipose-derived
mesenchymal stromal cell (AMSC) donors before cryopreservation (pre-freeze), immediately after rescue from cryopreservation (post-thaw), and 4 days
after revival from cryopreservation (4d Culture). a AMSCs were >90 % positive for classical surface markers across all manufacturing conditions, except
CD34 which was a negative marker. b Non-classical surface markers exhibited variability both in population positivity (%Gated) and mean fluorescence
intensity (MFI) as cells were processed through the various manufacturing conditions. One-way ANOVA and post-hoc testing were performed
to identify variables that were statistically significant at p < 0.05
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respectively. The increased percentage of positive cells
for CD271 and CD36 was also corroborated by a signifi-
cant increase in MFI (Fig. 5b). Further studies are re-
quired to determine the biological importance of the
increased abundance of CD271- and CD36-positive cells,
but it may indicate positive selection of more robust
cells or that recovery from cryopreservation is necessary
for expression of growth factor receptors (CD271/
NGFR) and fatty acid transporters (CD36). Collectively,
these results suggest that cryopreservation does not
modulate the expression of classical and non-classical
cell surface markers. However, recovery in culture may
allow optimal surface level expression of these proteins.
High-resolution surface marker gene expression analysis
of clinical-grade AMSCs grown in human platelet lysate
During the manufacturing process AMSCs are expanded
ex vivo to produce the large number of cells required for
therapeutic applications. Throughout the process it is
important to monitor the growth of the AMSCs and
particularly the confluence of the cultures (surface area
covered by cells), as these cells experience contact inhib-
ition. To evaluate whether cell surface marker gene ex-
pression was modulated by the confluent state of the
culture, RNA from proliferating (70–80 % confluent) and
confluent (100 % confluent) cultures was analyzed. Gene
expression analysis using the high-throughput qPCR panel
developed above revealed 29 genes that were up-regulated
greater than 2-fold in confluent cells and nine genes that
were 2-fold up-regulated in proliferating cells. Classical
surface markers CD44, CD105, and CD73 were not modu-
lated by confluency; however, both CD90 and CD34 were
>2-fold up-regulated in confluent cultures. Together, these
results indicate that cell surface markers are directly mod-
ulated by the tissue culture conditions.
Recently, high-resolution gene expression analysis
using RNA-seq technology was used to characterize
AMSCs inherent proliferative and differentiation poten-
tial [13]. Following our observations from qPCR profil-
ing of cell surface genes, we utilized both previously
published [13] and new RNA-seq data to evaluate the
expression of 707 genes encoding CD markers and re-
lated cell surface proteins as curated based on gene
ontology terms for four AMSC donors. It should be
noted that the RNA-seq data represented proliferating
and confluent samples as indicated by the expression of
cell cycle genes (Additional file 2: Figure S1). Genes that
were not expressed (0 RPKM) across all samples were
filtered out, which revealed that AMSCs express 551/
707 surface protein-encoding genes. Furthermore, RNA-
seq data also supported our initial qPCR findings, in
which surface markers expressed by AMSCs showed dis-
tinct clustering patterns of proliferating and confluent
samples (Fig. 6b, d, c).
To further characterize the AMSC surface transcrip-
tome, we filtered the 551 expressed surface protein-
encoding genes for expression >0.1 RPKM, and developed
gene lists for the constitutive, proliferating, or confluent
state. The gene lists were subjected to functional annota-
tion analysis using the public database DAVID 6.7 [30, 31]
(Table 2). Due to the selection of only cell surface protein-
encoding genes as the input, “Membrane,” “Signal,” and
“Plasma membrane” were commonly ranked among the
highly enriched categories. However, the categories
enriched in the constitutive group provide insight into the
functions of AMSCs, including “Signal Transduction,”
“Angiogenesis,” and “Immune response.” In the proliferat-
ing group of genes, categories including “Integrin,” “ECM-
receptor interaction,” and “Biosynthetic process” suggest
these cells up-regulate proteins involved in movement and
replication. Conversely, the group of genes characteristic
of the confluent state indicate processes involved in para-
crine signaling, including “Vesicle-mediated transport”
and “Regulation of transcription.” Together, these data
suggest that AMSCs express different levels of mRNAs for
CD markers in proliferative and confluent states.
Discussion
Numerous clinical trials are currently being performed
using AMSCs as a cellular therapy for various diseases
worldwide [32, 33]. Standardization of the production
procedures and accurate characterization of the MSC
product to ensure patient safety has been a significant
concern for regulatory agencies governing the approval
of biological license applications [2]. Our study identified
and validated the expression of 14 classical and non-
classical surface markers on clinical-grade AMSCs ex-
panded in hPL adherent to good manufacturing practices
(GMP-hPL). Furthermore, we evaluated surface marker
expression during processes for preparing cells for clinical
administration and demonstrated variability of these
markers with doublings/day and cryopreservation.
Traditionally AMSCs have been expanded with FBS as
part of the culture media to provide growth factors and
other proteins to support proliferation. However, potential
zoonotic pathogens and immunogenic reactions from FBS
are concerning for the clinical administration of MSCs,
which led to the development of nonzoonotic substitutes
including hPL [12, 34]. As part of the production of
clinical-grade AMSCs used in these studies, we expanded
our MSC product in GMP-hPL, which has previously
been shown to support proliferation and genomic stability
[12]. Furthermore, hPL contains proteins important for
healing, including FGF/EGF, TGF-β/BMP, and VEGF/
PDGF, which may facilitate AMSC growth and stability
[35]. However, due to the differences in composition of
FBS and hPL, including cytokines and growth factors,
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there exists the potential for the selection of different
adherent cell populations.
An AMSC cell population is characterized as one that
adheres to plastic, expresses characteristic surface
markers, and has tri-lineage potential [11]. Establishing
these criteria was an important step forward for
standardization of stem cell science and industry. This
study validated that clinical-grade AMSCs from 15 dif-
ferent donors met these established criteria and also
expressed a unique set of non-classical surface markers.
The AMSCs utilized in this investigation were cultured
in GMP-hPL, adhered to plastic, and uniformly
expressed the classical surface markers CD44, CD73,
CD90, and CD105 and did not express CD34. Although
(See figure on previous page.)
Fig. 6 High-resolution RNA-sequencing (RNA-seq) analysis of surface marker gene expression by proliferating and confluent adipose-derived
mesenchymal stromal cells (AMSCs). a Gene expression profiling using quantitative PCR for 69 cell surface protein-encoding genes reveals
some surface markers are differentially expressed between proliferating (~70–80 % confluent) and confluent (100 % confluent) AMSCs. Values
indicate fold-change (Log10 transformed) of confluent over proliferating, and are averages of samples from four different AMSC donors. Fold-change
analysis shows markers that are differentially expressed between proliferating and confluent cultures. To further evaluate differential surface marker
expression, RNA-seq was performed on proliferating and confluent AMSCs from four different donors. b Expression values for 551 cell surface genes
expressed at a magnitude >0 reads per kilobase per million (RPKM) by all AMSC donors were extracted from the RNA-seq data set and subjected to
hierarchical clustering analysis, which revealed distinct expression patterns for proliferating and confluent cells. c Representative graphs of genes
derived from RNA-seq analysis shows CD292/BMPR1A was constitutively expressed, CD168/HMMR was only expressed by proliferating cells, and
CD106/VCAM1 was only expressed in confluent cells
Table 2 Top 25 categories from a DAVID 6.7 analysis of cell surface proteins expressed on adipose-derived mesenchymal
stromal cells
Constitutive Proliferating Confluent
(n = 142, p > 0.05) (n = 104, up >1.4-fold, p < 0.05) (n = 79, up >1.4-fold, p < 0.05)
Rank Category (enrichment score) Category (enrichment score) Category (enrichment score)
1 Membrane (48.26) Signal (28.07) Membrane (24.12)
2 Signal (47.47) Membrane (27.82) Signal (18.65)
3 Plasma membrane (28.33) Cell adhesion (14.15) Plasma membrane (11.82)
4 Cell adhesion (9.99) Plasma membrane (12.38) Tetraspanin (3.97)
5 Signal transduction (8.17) Immunoglobulin-like (6.25) Protease/peptidase (3.95)
6 Tetraspanin (7.20) Tetraspanin (5.88) ABC transporter (3.93)
7 Lipoprotein (5.52) Integrin (5.75) Growth factor binding (3.82)
8 Angiogenesis (5.11) Response to wounding (4.85) Cell adhesion (3.39)
9 B cell activation/Fas pathway (5.08) Immunoglobulin-like V set (4.57) Secreted (3.30)
10 Cell migration (4.86) Metalloprotease (4.47) Semaphorin (2.95)
11 Apoptosis (4.68) Cell–cell adhesion (4.37) Immunoglobulin-like (2.95)
12 Semaphorin (4.63) Transferase (3.71) Immune cell activation (2.55)
13 Immune response (4.38) Semaphorin/integrin (3.56) Vesicle-mediated transport (2.40)
14 Calcium-mediated signaling (4.20) Transport (3.40) Cytokine–cytokine receptor interaction (2.33)
15 Cytokine binding (4.12) Extracellular matrix-receptor interaction (3.37) Cell migration (2.29)
16 Activation immune response (4.00) Cell motion (3.36) Integrin (2.24)
17 Cell motion (3.68) Differentiation (3.04) Glycoprotein metabolic process (2.07)
18 Protein kinase cascade (3.64) Epidermal growth factor (2.88) Cell proliferation (1.96)
19 Integrin (3.31) Low-density lipoprotein (2.32) Membrane fraction (1.93)
20 Tyrosine protein kinase (3.04) Biosynthetic process (2.20) Immunoglobulin V-set (1.84)
21 Immune cell activation (3.02) Secreted (2.13) Regulation of transcription (1.56)
22 Signal-anchor (3.01) Immune response (2.11) Response to wounding (1.48)
23 Low density lipoprotein receptor (2.91) Membrane fraction (2.04) Regulation of immune activation (1.38)
24 Stress-activated protein kinase (2.90) Magnesium ion binding (1.92) Protein kinase cascade (1.18)
25 Wnt receptor pathway (2.88) Cytokine binding (1.75) Carbohydrate binding (1.07)
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these markers uniformly define AMSCs, ours and other
studies have observed that these markers are unable to
distinguish donor differences, including variability in
proliferation or trophic activity [36]. Therefore, there is
an increased need to identify additional markers that not
only define AMSCs but also have the potential to cap-
ture biological and manufacturing variability, as well as
clinical performance.
Beyond serving as markers for cell characterization,
surface proteins carry out important biological functions
and are critical for cell-to-cell contact, extracellular
matrix interactions, signal transduction, and transporta-
tion of molecules across the plasma membrane. Our
study examined the expression of all plasma membrane
protein-encoding genes (including CD markers, recep-
tors, integrins, and transporters) by RNA-seq and identi-
fied 551/707 genes that were expressed on AMSCs.
Previous studies of AMSCs and BMSCs evaluated the
expression of 200–242 surface markers using mass spec-
troscopy or BD Lyoplate technology with flow cytometry
techniques [21–24]. Together, our and others’ studies
have identified and characterized a finite number of sur-
face proteins present on the AMSC cell surface under
standard conditions. A comparison of surface marker ex-
pression by qPCR expression and flow cytometry
showed partial concordance, with seven out of nine
markers showing similar trends (Fig. 4). Our results
show that gene expression and flow cytometry tech-
niques can be used to identify novel cell surface markers
in AMSC populations. However, confirmation of cell
surface proteins by flow cytometry is still necessary to
confirm cell surface marker expression, as it is the pri-
mary technique used in the clinical setting.
Our data also reveal differential expression of mRNAs
for CD markers in proliferative and post-proliferative
AMSCs. Previous studies have also characterized the
gene expression effects of confluence and doubling times
on AMSCs and BMSCs [13, 37]. These studies and ours
suggest that culture conditions, including proliferation
state and population doublings, may affect the differenti-
ation potential of AMSCs. In particular, mRNA expres-
sion of some surface markers is restricted to either the
proliferating or confluent state (Fig. 6c). However, fur-
ther studies are required to determine whether manufac-
turing conditions (e.g., length of culture and growth
rate), as well as biological factors (e.g., donor age and
disease status) would impact therapeutic potential. Our
studies indicate that at least some variation in cell sur-
face expression may emerge during AMSC production
depending on the growth rate of the cell population.
Currently there is no standardization of release criteria
for MSC products, and studies that define their criteria
usually include the markers described by the ISCT and
IFATS [2, 38]. Through the use of gene expression
profiling techniques and flow cytometry, our study iden-
tified and validated nine non-classical markers that may
help further characterize hPL-expanded AMSCs and im-
prove current release criteria. In our study we validated
the expression of CD163, CD271, CD200, CD36, CD274,
CD146, CD248, CD140B, and CD276. These markers
are also expressed on FBS-expanded AMSCs [22–25,
39–42]. Our study also identified CD163, a monocyte
and macrophage marker, as a negative AMSC marker,
which may be useful for characterizing clinical-grade
MSC populations [43].
We also described the expression of the known
immune-regulatory markers CD274 (B7H1/PD-L1) and
CD276 (B7H3) on hPL-expanded AMSCs. Traditionally,
mature dendritic cells produce soluble CD274 and
CD276 [44]. However, the current results demonstrate
that AMSCs grown in hPL also express these markers
on the cell surface. Our results show that CD276 is
highly expressed and may be expressed ubiquitously
with other traditional markers such as CD73, CD105,
and CD90. Similarly, CD274 is highly expressed, but
shows greater variability between donors. The functional
role of CD274 and CD276 on AMSCs has yet to be
characterized; however, CD274-positive BMSCs have
been shown to regulate T-cell proliferation and Th17
polarization [45, 46]. Furthermore, recent studies have
shown that interferon gamma (IFNγ) priming or licens-
ing of BMSCs may also up-regulate CD274 and enhance
MSC-mediated T-cell inhibition [47, 48]. However, the
function of CD276 remains controversial as this mol-
ecule may act as a co-stimulatory molecule for T-cell ac-
tivation and selectively stimulates the production of
IFNγ [49], or may inhibit T-cell proliferation [50].
CD274 and CD276 have the potential to serve as pre-
dictive clinical markers for MSC immunomodulatory ac-
tivity. Isolation and characterization of CD274-positive
and CD276-positive cells may determine whether these
cells represent distinct subpopulations with enhanced
immune-regulatory effects. Further studies correlating
these markers with patient outcomes in clinical trials
would also help to elucidate the role of these markers in
hPL-expanded AMSCs.
Storage and administration of the MSC product for
cell therapy may depend on the disease and the institu-
tional infrastructure. Current clinical trials administer
MSC products either without cryopreservation, cryopre-
served and thawed, or allowed to recover for 4 days in
culture. Previous studies have demonstrated reduced im-
munosuppressive properties of MSCs immediately
thawed after cryopreservation, and that these properties
were restored as early as 24 h after placing in tissue cul-
ture [51]. Samples from three of our five donors ana-
lyzed showed a slight decrease in CD248 expression
between pre-freeze and post-thaw samples. The decrease
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in surface marker expression could be attributed to
damage to the cell surface of the protein that reduces
antibody-binding efficiency or, potentially, the sensitivity
of CD248 expression to the metabolic state of the cell.
We also observed a significant increase in CD105
expression between pre-freeze and post-thaw samples, as
well as a significant increase in surface marker expres-
sion over 4 days for CD271, CD36, and, to a lesser ex-
tent, CD44. These results support the work of Francois
and colleagues [51], whereby the recovery of AMSCs in
culture for up to 4 days can result in maximal surface
marker expression. Together, these data suggest that
surface marker expression is modulated during the cryo-
preservation process and that it may be important for
cell function to allow cells to recover for up to 4 days.
Conclusions
We evaluated the expression of classical and non-
classical surface markers across a cohort of 15 donors
from various disease backgrounds. Our results demon-
strate that our manufacturing procedures consistently
produce an AMSC population that uniformly expresses
classical MSC surface markers. We also characterized
the expression of nine non-classical surface markers that
may be used to further characterize the AMSC product.
The known immunomodulatory markers CD274 and
CD276 are also highly expressed on the surface of
AMSCs and may be able to predict their immunomodu-
latory activity and clinical efficacy. Future clinical trials
will help us to determine which surface markers are the
best predictors of clinical outcomes for patients.
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